Edition:
United States

Pacira Pharmaceuticals Inc (PCRX.O)

PCRX.O on Nasdaq

46.10USD
11:24am EDT
Change (% chg)

$-1.50 (-3.15%)
Prev Close
$47.60
Open
$47.60
Day's High
$47.65
Day's Low
$45.95
Volume
118,119
Avg. Vol
1,100,518
52-wk High
$65.64
52-wk Low
$29.95

Latest Key Developments (Source: Significant Developments)

Trinity and Pacira announce collaboration to decrease opioid use nationwide
Thursday, 16 Mar 2017 07:30am EDT 

Pacira Pharmaceuticals Inc : Trinity Health and Pacira Pharmaceuticals announce collaboration to decrease opioid use nationwide .Co, Pacira Pharmaceuticals announced they will collaborate to develop an alternative approach to opioids for pain management.  Full Article

Pacira Pharmaceuticals announces proposed offering of $300 million aggregate principal amount of convertible senior notes
Monday, 6 Mar 2017 04:01pm EST 

Pacira Pharmaceuticals Inc : Announces proposed offering of $300 million aggregate principal amount of convertible senior notes . Announced it intends to offer $300 million aggregate principal amount of convertible senior notes due 2022 .Intends to use portion of net proceeds to enter into agreements with certain holders of 3.25 pct convertible senior notes due 2019.  Full Article

Pacira Pharmaceuticals reports Q4 adj. earnings per share $0.09
Wednesday, 1 Mar 2017 07:30am EST 

Pacira Pharmaceuticals Inc : Pacira Pharmaceuticals reports 2016 financial results and provides business update . Q4 non-GAAP earnings per share $0.09 . Q4 GAAP loss per share $0.11 . Q4 revenue $72.9 million versus I/B/E/S view $73.1 million . Q4 earnings per share view $0.01 -- Thomson Reuters I/B/E/S . Pacira Pharmaceuticals Inc sees FY 2017 exparel net product sales of $290 million to $310 million . Sees 2017 exparel net product sales of $290 million to $310 million .Pacira Pharmaceuticals Inc sees FY 2017 non-GAAP gross margins of approximately 70 pct.  Full Article

Pacira Pharmaceuticals collaborates with Depuy Synthes to support promotion, education and training of exparel in orthopedics
Wednesday, 25 Jan 2017 07:30am EST 

Pacira Pharmaceuticals Inc : Pacira Pharmaceuticals announces collaboration with Depuy Synthes to support promotion, education and training of Exparel in orthopedics .Pacira Pharmaceuticals - initiation of agreement with Depuy Synthes sales to market and promote use of exparel for orthopedic procedures in U.S. market.  Full Article

Pacira Pharmaceuticals Q2 GAAP loss per share $0.21
Thursday, 4 Aug 2016 07:30am EDT 

Pacira Pharmaceuticals Inc : Q2 GAAP loss per share $0.21 . Q2 non-GAAP earnings per share $0.19 . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S .Q2 revenue $69.6 million versus I/B/E/S view $67.1 million.  Full Article

Pacira Pharmaceuticals to pay termination fee of about $7.3 mln to CrossLink
Friday, 1 Jul 2016 07:01am EDT 

Pacira Pharmaceuticals : In connection with termination of agreement, fee based on percentage of earned performance-based fees will be due to CrossLink . Termination fee in connection with agreement with CrossLink Bioscience related to promotion and sale of exparel . The fee, estimated to be about $7.3 million, is payable to CrossLink quarterly over two years beginning in Q4 of 2016 Source: (http://1.usa.gov/29ah9lF ) Further company coverage: [PCRX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Pacira Pharmaceuticals announces promotion of James S. Scibetta to President
Tuesday, 20 Oct 2015 07:30am EDT 

Pacira Pharmaceuticals:Announces promotion of James S. Scibetta to President.Says Scibetta will continue to serve as CFO while the company conducts a search for his successor.Says Dave Stack Remains Chairman and Chief Executive Officer.  Full Article

Pacira Pharmaceuticals announces completion of end-of-review process with FDA regarding EXPAREL sNDA for Nerve Block
Thursday, 28 May 2015 06:30am EDT 

Pacira Pharmaceuticals:Completes an End-of-Review process with the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for the use of EXPAREL for administration as a nerve block to provide postsurgical analgesia.Pacira requested an End-of-Review meeting in March 2015 following its receipt of a complete response letter (CRL).  Full Article

More From Around the Web

BRIEF-Trinity and Pacira announce collaboration to decrease opioid use nationwide

* Trinity Health and Pacira Pharmaceuticals announce collaboration to decrease opioid use nationwide